Gypenoside XVII

Description: Gypenoside XVII (Gynosaponin S) confers protection against Abeta25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, activation of Nrf2/ARE/HO-1 and inactivation of GSK-3beta pathways. Target: GSK-3, Estrogen Receptor/ERR, Endogenous Metabolite. Smiles: [H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@]3([H])CC[C@@]21C)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O. References: Shin KC, et al. Biotechnol Lett. 2014 Jun,36(6):1287-93.